BIOPHARMA
By
Could Servier’s $450M Fragile X Acquisition Redefine Its Neurology Strategy?
Key Highlights Strategic Fit for ServierThis marks Servier’s first neurology asset acquisition, aligned with its 2030 strategy to…
Will GSK’s Fluviral Supply Strengthen Canada’s Seasonal Flu Preparedness?
Key Highlights Public Health ImpactAnnual flu vaccination remains the most effective tool to reduce flu-related risks. Vulnerable populations…
Could Takeda’s Landmark Phase 3 Oveporexton Results Redefine the Standard of Care in Narcolepsy Type 1?
Key Highlights Clinical Breakthroughs Across EndpointsPatients treated with oveporexton demonstrated marked improvements in excessive daytime sleepiness, with most…
Could Roche’s New Vabysmo Data Redefine Long-Term Care in “wet” age-related macular degeneration (nAMD)?
Key Highlights Durability Demonstrated in AVONELLE-XRoche presented four-year data from AVONELLE-X at the Euretina 2025 Congress, showing that…
U.S. FDA Awards National Priority Review Vouchers to Merck for Cholesterol and Cancer Drug Candidates
United States — The U.S. Food and Drug Administration (FDA) has awarded Commissioner’s National Priority Review Vouchers to…
Pfizer Provides 2026 Financial Guidance and Updates 2025 Revenue Outlook
New York, NY – Pfizer Inc. (NYSE: PFE) today announced its financial guidance for the full year 2026…
